doi:10.3969/j.issn.1673-8640.2015.05.032

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 7

[1]	BINGLE L,CROSS SS,HIGH AS,et al.WFDC2(HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarci-nomas of the lung[J].Respir Res,2006,7:61.
[2]	GALGANO MT,HAMPTON GM,FRIERSON HF JR.Comprehensive analysis of HE4 expression in normal and malignant human tissues[J].Mod Pathol,2006,19(6):847-853.
[3]	HELLSTRÖM I,RAYCRAFT J,HAYDEN-LEDBETTER M,et al. The HE4(WFDC2) protein is a biomarker for ovarian carcinoma[J].Cancer Res,2003,63(13):3695-3700.
[4]	曹泽毅. 中华妇产科学[M]. 北京:人民卫生出版社,1999:1545-1551.
[5]	REDMAN C,BRADGATE MG,ROLLASON TP,et al.Cancer antigen CA125 in epithelial ovarian cancer: immunohistochemical expression before and after chemotherapy[J]. Eur J Cancer Clin Oncol,1988,24(8): 1381-1382.
[6]	MOLINA R,ESCUDERO JM,AUGÉ JM,et al.HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases[J]. Tumor Biol, 2011,32(6):1087-1095.
[7]	KARLSEN MA,SANDHU N,HØGDALL C,et al. Evaluation of HE4,CA125,risk of ovarian malignancy algorithm(ROMA) and risk of malignancy index(RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol,2012,127(2):379-383.

组别	CA125			HE4			CA125+HE4
组别	阳性	阴性	合计	阳性	阴性	合计	阳性	阴性	合计
子宫恶性病变组	6	32	38	2	36	38	6	32	38
子宫良性病变组	19	77	96	8	88	96	20	76	96
合计	25	109	134	10	124	134	26	108	134

组别	CA125			HE4			CA125+HE4
组别	阳性	阴性	合计	阳性	阴性	合计	阳性	阴性	合计
子宫恶性病变组	6	32	38	2	36	38	6	32	38
子宫良性病变组	19	77	96	8	88	96	20	76	96
合计	25	109	134	10	124	134	26	108	134

组别	CA125			HE4			CA125+HE4
组别	阳性	阴性	合计	阳性	阴性	合计	阳性	阴性	合计
卵巢癌组	32	3	35	29	6	35	33	2	35
卵巢良性病变组	20	37	57	6	51	57	4	53	57
合计	52	40	92	35	57	92	37	55	92

组别	CA125			HE4			CA125+HE4
组别	阳性	阴性	合计	阳性	阴性	合计	阳性	阴性	合计
卵巢癌组	32	3	35	29	6	35	33	2	35
卵巢良性病变组	20	37	57	6	51	57	4	53	57
合计	52	40	92	35	57	92	37	55	92

项目	子宫恶性肿块		卵巢癌
项目	灵敏度	特异性	灵敏度	特异性
CA125	15.8	80.2	91.4	64.9
HE4	5.3	91.7	82.9	89.5
CA125+HE4	15.8	79.2	94.3	93.0

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 7

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.